In the Kitahima et al. [58] nomogram, unfavorable prognosis in patients treated with 223Ra after the EMA amendment was based on some characteristics such as pre-treatment with chemotherapy, lymphadenopathies, high BM tumor burden (depicted by the number of BM at the BS and PSA levels), and low hemoglobin levels. The gene discussed is KLK3; the disease is Lymphadenopathy.